ESH CLL 2022 | The importance of novel mouse models in our understanding of CLL
Elisa ten Hacken, PhD, Dana Farber Cancer Institute, Boston, MA, shares some updates on recent advances in the development of mouse models and their use in chronic lymphocytic leukemia (CLL). Dr ten Hacken first discusses how novel models are able to more accurately recapitulate human disease and allow researchers to better understand mutations and pathways involved in CLL, compared to the commonly used TCL1 mouse model. Dr ten Hacken then draws focus on the Ikzf3 mouse model, which has shown researchers how aberrant B-cell receptor signaling may influence the development of disease and impact patient response to therapies. To conclude, Dr ten Hacken mentions that newer, genetically faithful mouse models may help to guide precision medicine better than previously used models. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
